{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:53:27Z","timestamp":1794009207950,"version":"4.8.0"},"reference-count":62,"publisher":"Informa UK Limited","issue":"10","funder":[{"DOI":"10.13039\/501100004035","name":"Jordan University of Science and Technology","doi-asserted-by":"publisher","award":["583\/2022"],"award-info":[{"award-number":["583\/2022"]}],"id":[{"id":"10.13039\/501100004035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2023,10,3]]},"DOI":"10.1080\/14740338.2023.2223957","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T11:41:29Z","timestamp":1686310889000},"page":"957-965","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Patterns of adverse drug reactions in Jordan: a retrospective analysis of the National Pharmacovigilance Data Registry (2015\u20132021)"],"prefix":"10.1080","volume":"22","author":[{"given":"Nizar M.","family":"Mhaidat","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan"},{"name":"Jordan Food and Drug Administration, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2466-4763","authenticated-orcid":false,"given":"Osama Y.","family":"Alshogran","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8345-4048","authenticated-orcid":false,"given":"Shoroq M.","family":"Altawalbeh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaber M","family":"Jaber","sequence":"additional","affiliation":[{"name":"Rational Drug Use and Pharmacovigilance Department, Jordan Food and Drug Administration, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayaa A.","family":"Banat","sequence":"additional","affiliation":[{"name":"Rational Drug Use and Pharmacovigilance Department, Jordan Food and Drug Administration, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana S.","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Rational Drug Use and Pharmacovigilance Department, Jordan Food and Drug Administration, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worood","family":"Alabsi","sequence":"additional","affiliation":[{"name":"Jordan Food and Drug Administration, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"issue":"9","key":"e_1_3_5_3_1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1377\/hlthaff.2020.00284","article-title":"Contributions of public health, pharmaceuticals, and other medical care to US life expectancy changes, 1990-2015","volume":"39","author":"Buxbaum JD","year":"2020","unstructured":"Buxbaum JD, Chernew ME, Fendrick AM, et al. Contributions of public health, pharmaceuticals, and other medical care to US life expectancy changes, 1990-2015. Health Aff. 2020 Sep;39(9):1546\u20131556.","journal-title":"Health Aff"},{"key":"e_1_3_5_4_1","doi-asserted-by":"crossref","first-page":"j4623","DOI":"10.1136\/bmj.j4623","article-title":"Improving quality of life relies on valid outcome measures as well as drugs","volume":"359","author":"Jones RC","year":"2017","unstructured":"Jones RC, Masoli M, Lanario JW, et al. Improving quality of life relies on valid outcome measures as well as drugs. BMJ. 2017 Oct 12;359:j4623.","journal-title":"BMJ"},{"key":"e_1_3_5_5_1","unstructured":"WHO. Safety of medicines: a guide to detecting and reporting adverse drug reactions. 26 Mar 2023. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/67378\/WHO_EDM_QSM_2002.2.pdf;jsessionid=30D671474D9B761620C6D8E24AB1777C?sequence=1"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0019-9"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-5-481"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.07.012"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620938595"},{"issue":"15","key":"e_1_3_5_10_1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"Lazarou J","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15;279(15):1200\u20131205.","journal-title":"JAMA"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0281-0"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2441-5"},{"issue":"7","key":"e_1_3_5_13_1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14740338.2018.1491547","article-title":"The economic burden of preventable adverse drug reactions: a systematic review of observational studies","volume":"17","author":"Formica D","year":"2018","unstructured":"Formica D, Sultana J, Cutroneo PM, et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin Drug Saf. 2018 Jul;17(7):681\u2013695.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"e_1_3_5_14_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11586620-000000000-00000","article-title":"Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance","volume":"34","author":"Borg JJ","year":"2011","unstructured":"Borg JJ, Aislaitner G, Pirozynski M, et al. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf. 2011 Mar 1;34(3):187\u2013197.","journal-title":"Drug Saf"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.13005\/bpj\/1112"},{"issue":"11","key":"e_1_3_5_16_1","doi-asserted-by":"crossref","first-page":"e010643","DOI":"10.1136\/bmjopen-2015-010643","article-title":"Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.Gov registry","volume":"6","author":"Zhang X","year":"2016","unstructured":"Zhang X, Zhang Y, Ye X, et al. Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.Gov registry. BMJ Open. 2016 Nov 23;6(11):e010643.","journal-title":"BMJ Open"},{"key":"e_1_3_5_17_1","unstructured":"Centre Ummembers of the who programme for international drug monitoring 2022. 26 Mar 2023. Available from: https:\/\/who-umc.org\/about-the-who-programme-for-international-drug-monitoring\/member-countries\/"},{"key":"e_1_3_5_18_1","unstructured":"WHO. The importance of pharmacovigilance 2002. 26 Mar 2023. Available from: https:\/\/www.who.int\/publications\/i\/item\/10665-42493"},{"issue":"2","key":"e_1_3_5_19_1","first-page":"145","article-title":"A retrospective review of serious adverse drug reaction reports in the nigerian vigiflow database from september 2004 to December 2016","volume":"33","author":"Ogar CK","year":"2019","unstructured":"Ogar CK, Abiola A, Yuah D, et al. A retrospective review of serious adverse drug reaction reports in the nigerian vigiflow database from september 2004 to December 2016. Pharmaceut Med. 2019 Apr;33(2):145\u2013157.","journal-title":"Pharmaceut Med"},{"issue":"1","key":"e_1_3_5_20_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jsps.2021.08.014","article-title":"Patterns of adverse drug reactions (ADRs) in Saudi Arabia","volume":"30","author":"Bin Yousef N","year":"2022","unstructured":"Bin Yousef N, Yenugadhati N, Alqahtani N, et al. Patterns of adverse drug reactions (ADRs) in Saudi Arabia. Saudi Pharm J. 2022 Jan;30(1):8\u201313.","journal-title":"Saudi Pharm J"},{"issue":"1","key":"e_1_3_5_21_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40801-015-0054-1","article-title":"Adverse drug reaction reporting pattern in turkey: analysis of the national database in the context of the first pharmacovigilance legislation","volume":"3","author":"Ozcan G","year":"2016","unstructured":"Ozcan G, Aykac E, Kasap Y, et al. Adverse drug reaction reporting pattern in turkey: analysis of the national database in the context of the first pharmacovigilance legislation. Drugs Real World Outcomes. 2016 Mar;3(1):33\u201343.","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"e_1_3_5_22_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40360-021-00520-y","article-title":"Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs","volume":"22","author":"Dubrall D","year":"2021","unstructured":"Dubrall D, Leitzen S, Toni I, et al. Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs. BMC Pharmacol Toxicol. 2021 Oct 7;22(1):56.","journal-title":"BMC Pharmacol Toxicol"},{"key":"e_1_3_5_23_1","doi-asserted-by":"crossref","first-page":"e40080","DOI":"10.2196\/40080","article-title":"Reporting, monitoring, and handling of adverse drug reactions in Australia: scopingreview","volume":"9","author":"Fossouo Tagne J","year":"2023","unstructured":"Fossouo Tagne J, Yakob RA, Dang TH, et al. Reporting, monitoring, and handling of adverse drug reactions in Australia: scopingreview. JMIR Public Health Surveill. 2023 Jan 16;9:e40080.","journal-title":"JMIR Public Health Surveill"},{"issue":"5","key":"e_1_3_5_24_1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jsps.2018.03.002","article-title":"Effect of educational intervention on healthcare providers knowledge and perception towards pharmacovigilance: a tertiary teaching hospital experience","volume":"26","author":"Abu Farha R","year":"2018","unstructured":"Abu Farha R, Abu Hammour K, Rizik M, et al. Effect of educational intervention on healthcare providers knowledge and perception towards pharmacovigilance: a tertiary teaching hospital experience. Saudi Pharm J. 2018 Jul;26(5):611\u2013616.","journal-title":"Saudi Pharm J"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jep.12683"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.4103\/picr.PICR_4_18"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574884713666180308151805"},{"issue":"5","key":"e_1_3_5_28_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/inthealth\/ihy029","article-title":"A survey on the knowledge, attitudes and practices of physicians towards pharmacovigilance in Jordanian health centres","volume":"10","author":"Shroukh WA","year":"2018","unstructured":"Shroukh WA, Shakhatreh FM, Yasein NA, et al. A survey on the knowledge, attitudes and practices of physicians towards pharmacovigilance in Jordanian health centres. Int Health. 2018 Sep 1;10(5):363\u2013370.","journal-title":"Int Health"},{"key":"e_1_3_5_29_1","unstructured":"ATC. Anatomical Therapeutic Chemical (ATC) Classification. cited 26 Mar 2023. Available online: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification"},{"key":"e_1_3_5_30_1","unstructured":"MedDRA. Medical Dictionary for Regulatory Activities. 26 Mar 2023. Available online: https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202211_30172"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1043_22"},{"issue":"6","key":"e_1_3_5_33_1","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.3390\/ijerph19063264","article-title":"Inconsistent Country-wide reporting of adverse drug reactions to antimicrobials in Sierra Leone (2017\u20132021): a wake-up call to improve reporting","volume":"19","author":"Thomas F","year":"2022","unstructured":"Thomas F, Abiri OT, Komeh JP, et al. Inconsistent Country-wide reporting of adverse drug reactions to antimicrobials in Sierra Leone (2017\u20132021): a wake-up call to improve reporting. IJERPH. 2022 Mar 10;19(6):3264.","journal-title":"IJERPH"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2118712"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932010-00002"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-016-0083-4"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.4103\/1995-7645.338436"},{"issue":"23","key":"e_1_3_5_38_1","first-page":"393","article-title":"Frequent adverse drug reactions, and medication groups under suspicion","volume":"115","author":"Dubrall D","year":"2018","unstructured":"Dubrall D, Schmid M, Alesik E, et al. Frequent adverse drug reactions, and medication groups under suspicion. Dtsch Arztebl Int. 2018 Jun 8;115(23):393\u2013400.","journal-title":"Dtsch Arztebl Int"},{"issue":"10","key":"e_1_3_5_39_1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/14740338.2021.1938539","article-title":"Prevalence, characteristics, and reporting of adverse drug reactions in an Australian hospital: a retrospective review of hospital admissions due to adverse drug reactions","volume":"20","author":"Li R","year":"2021","unstructured":"Li R, Curtis K, Zaidi STR, et al. Prevalence, characteristics, and reporting of adverse drug reactions in an Australian hospital: a retrospective review of hospital admissions due to adverse drug reactions. Expert Opin Drug Saf. 2021 Oct;20(10):1267\u20131274.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"e_1_3_5_40_1","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s11096-015-0185-1","article-title":"Adverse drug reactions experience in a teaching hospital in Jordan","volume":"37","author":"Alsbou M","year":"2015","unstructured":"Alsbou M, Alzubiedi S, Alzobi H, et al. Adverse drug reactions experience in a teaching hospital in Jordan. Int J Clin Pharm. 2015 Dec;37(6):1188\u20131193.","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"e_1_3_5_41_1","first-page":"478","article-title":"Drug-induced admissions to medical wards at jordan university hospital","volume":"36","author":"Gharaibeh M","year":"1998","unstructured":"Gharaibeh M, Zmeili S, Abu-Rajab A, et al. Drug-induced admissions to medical wards at jordan university hospital. Int J Clin Pharmacol Ther. 1998 Sep;36(9):478\u2013482.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"e_1_3_5_42_1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/vaccines9060556","article-title":"Side effects and perceptions following COVID-19 vaccination in jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects","volume":"9","author":"Hatmal MM","year":"2021","unstructured":"Hatmal MM, Al-Hatamleh MAI, Olaimat AN, et al. Side effects and perceptions following COVID-19 vaccination in jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines (Basel). 2021 May 26;9(6):556.","journal-title":"Vaccines (Basel)"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.756633"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.808370"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1187"},{"issue":"11","key":"e_1_3_5_46_1","first-page":"e19424","article-title":"Adverse drug reactions in the pediatric population: findings from the Adverse Drug Reaction Monitoring Center of a Teaching Hospital in Odisha (2015-2020)","volume":"13","author":"Tripathy R","year":"2021","unstructured":"Tripathy R, Das S, Das P, et al. Adverse drug reactions in the pediatric population: findings from the Adverse Drug Reaction Monitoring Center of a Teaching Hospital in Odisha (2015-2020). Cureus. 2021 Nov;13(11):e19424.","journal-title":"Cureus"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03262002"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240276"},{"issue":"4","key":"e_1_3_5_49_1","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cpt.1310","article-title":"Identifiability of biologicals in adverse drug reaction reports received from european clinical practice","volume":"105","author":"Vermeer NS","year":"2019","unstructured":"Vermeer NS, Giezen TJ, Zastavnik S, et al. Identifiability of biologicals in adverse drug reaction reports received from european clinical practice. Clin Pharmacol Ther. 2019 Apr;105(4):962\u2013969.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00965"},{"issue":"6","key":"e_1_3_5_51_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cgh.2007.02.016","article-title":"Serious adverse events with infliximab: analysis of spontaneously reported adverse events","volume":"5","author":"Hansen RA","year":"2007","unstructured":"Hansen RA, Gartlehner G, Powell GE, et al. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007 Jun;5(6):729\u2013735.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"e_1_3_5_52_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5414\/CP204060","article-title":"Epidemiology and evaluation of adverse drug reactions in a Korean hospital database for spontaneous reports in the period 2009 to 2018","volume":"60","author":"Jeong HS","year":"2022","unstructured":"Jeong HS, Chun BC, Kang DY, et al. Epidemiology and evaluation of adverse drug reactions in a Korean hospital database for spontaneous reports in the period 2009 to 2018. Int J Clin Pharmacol Ther. 2022 Jul;60(7):291\u2013298.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098615615472"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-24.1.4"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.167099"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00964"},{"issue":"1","key":"e_1_3_5_57_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40360-022-00603-4","article-title":"Pharmacovigilance of cutaneous adverse drug reactions in associations with drugs and medical conditions: a retrospective study of hospitalized patients","volume":"23","author":"Zheng L","year":"2022","unstructured":"Zheng L, Jin HB, Guan YY, et al. Pharmacovigilance of cutaneous adverse drug reactions in associations with drugs and medical conditions: a retrospective study of hospitalized patients. BMC Pharmacol Toxicol. 2022 Aug 10;23(1):62.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"8","key":"e_1_3_5_58_1","first-page":"428","article-title":"Reducing errors with injectable medications: unlabeled syringes are surprisingly common","volume":"35","author":"Grissinger M","year":"2010","unstructured":"Grissinger M. Reducing errors with injectable medications: unlabeled syringes are surprisingly common. P T. 2010 Aug;35(8):428\u2013451.","journal-title":"P T"},{"issue":"1","key":"e_1_3_5_59_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ejhpharm-2018-001624","article-title":"Incidence and prevalence of intravenous medication errors in the UK: a systematic review","volume":"27","author":"Sutherland A","year":"2020","unstructured":"Sutherland A, Canobbio M, Clarke J, et al. Incidence and prevalence of intravenous medication errors in the UK: a systematic review. Eur J Hosp Pharm. 2020 Jan;27(1):3\u20138.","journal-title":"Eur J Hosp Pharm"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.702"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.875426"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S178297"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253588"},{"key":"e_1_3_5_64_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ymeth.2016.07.023","article-title":"Improving drug safety: from adverse drug reaction knowledge discovery to clinical implementation","volume":"110","author":"Tan Y","year":"2016","unstructured":"Tan Y, Hu Y, Liu X, et al. Improving drug safety: from adverse drug reaction knowledge discovery to clinical implementation. Methods. 2016 Nov 1;110:14\u201325.","journal-title":"Methods"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2023.2223957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T12:58:09Z","timestamp":1695301089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2023.2223957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,3]]}},"alternative-id":["10.1080\/14740338.2023.2223957"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2023.2223957","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}